NASDAQ:THTX - Theratechnologies Stock Price, Forecast & News

Theratechnologies' stock was trading at $2.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, THTX stock has decreased by 28.3% and is now trading at $1.57. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Theratechnologies.

Theratechnologies is scheduled to release its next quarterly earnings announcement on Thursday, April 2nd 2020. View our earnings forecast for Theratechnologies.

Theratechnologies Inc. (NASDAQ:THTX) issued its earnings results on Tuesday, February, 25th. The company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.02. The company had revenue of $16.40 million for the quarter, compared to the consensus estimate of $16.48 million. Theratechnologies had a negative return on equity of 37.48% and a negative net margin of 19.77%. View Theratechnologies' earnings history.

2 brokers have issued 1 year price targets for Theratechnologies' stock. Their forecasts range from $5.80 to $95.50. On average, they expect Theratechnologies' share price to reach $50.65 in the next twelve months. This suggests a possible upside of 3,126.1% from the stock's current price. View analysts' price targets for Theratechnologies.

News coverage about THTX stock has trended very positive recently, InfoTrie reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Theratechnologies earned a coverage optimism score of 4.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutTheratechnologies.

Theratechnologies saw a drop in short interest in the month of March. As of March 13th, there was short interest totaling 1,074,600 shares, a drop of 22.7% from the February 27th total of 1,390,000 shares. Based on an average daily volume of 140,900 shares, the days-to-cover ratio is presently 7.6 days. Currently, 1.4% of the shares of the stock are short sold. View Theratechnologies' Current Options Chain.

Some companies that are related to Theratechnologies include ANI Pharmaceuticals (ANIP), Akero Therapeutics (AKRO), Sinovac Biotech (SVA), DiaMedica Therapeutics (DMCAF), Atreca (BCEL), AC Immune (ACIU), Kura Oncology (KURA), Morphic (MORF), RAPT Therapeutics (RAPT), G1 Therapeutics (GTHX), Catalyst Pharmaceuticals (CPRX), Provention Bio (PRVB), Neoleukin Therapeutics (NLTX), Avedro (AVDR) and Basilea Pharmaceutica (BPMUF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Alibaba Group (BABA), Theratechnologies (TH), EXACT Sciences (EXAS), Aimmune Therapeutics (AIMT), Dropbox (DBX), Alphabet (GOOG), Intercept Pharmaceuticals (ICPT), LYFT (LYFT), Roku (ROKU) and Tesla (TSLA).

Theratechnologies trades on the NASDAQ under the ticker symbol "THTX."

Theratechnologies' stock is owned by a variety of retail and institutional investors. Top institutional investors include Caisse DE Depot ET Placement DU Quebec (2.60%), Boston Private Wealth LLC (1.08%), Stifel Financial Corp (0.31%), Swiss National Bank (0.19%), Renaissance Technologies LLC (0.14%) and Advisor Group Inc. (0.13%).

THTX stock was sold by a variety of institutional investors in the last quarter, including Boston Private Wealth LLC.

THTX stock was bought by a variety of institutional investors in the last quarter, including Caisse DE Depot ET Placement DU Quebec, Stifel Financial Corp, Swiss National Bank, Renaissance Technologies LLC, Advisor Group Inc., PNC Financial Services Group Inc., Belpointe Asset Management LLC, and Bank of Montreal Can.

Shares of THTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of THTX stock can currently be purchased for approximately $1.57.

Theratechnologies has a market capitalization of $120.81 million and generates $63.22 million in revenue each year. The company earns $-12,500,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. Theratechnologies employs 32 workers across the globe. View additional information about Theratechnologies.

The official website for Theratechnologies is http://www.theratech.com/.

Theratechnologies' mailing address is 2015 Peel Street 5th Floor, MONTREAL A8, H3A 1T8. The company can be reached via phone at 514-336-7800 or via email at [email protected]